APYX · Apyx Medical Corp
$3.85
-0.04 (-1.03%)
At close · Jul 28
Market Cap
$162.89M
Shares
41.87M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.89
Open$3.97
Day$3.84–3.97
52W$1.59–5.08
Avg vol 30d99K
Short int252K · 0.6% float · 3.9d
Short vol33%
Last earningsMay 27, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Up next
Next earnings call
Aug 26, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−8%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
66%
mid-range
Momentum
relative strength
1-month return
−7%
trailing
6-month return
−3%
trailing
YTD return
+11%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Distributing
8 of 67 funds reported for Jun 30 · net -20.9K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.60% of float · ▲ +42.0% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
67 holders — near 3-yr high, broad support
Squeeze score
51
elevated · 0–100
Fundamentals
Revenue growth
+10%
Y/Y
Gross margin
63%
expanding
EPS growth
+19%
Y/Y
Free cash flow
$-9.1M
Balance sheet
$3.1M
net debt
Quant / Vol
risk profile
Volatility
83%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
7.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total revenue
· full year 2026
Initiated
$59M – $60M
prior FY $52.84M
midpoint +12.6% Y/Y
Surgical Aesthetics revenue
· full year 2026
Initiated
$54M – $55M
OEM revenue
· full year 2026
Initiated
$5M
Operating expenses
· full year 2026
Initiated
up to $45M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
66%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 50d above 200d
Institutional flow
Distributing
8 of 67 funds reported for Jun 30 · net -20.9K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.60% of float · ▲ +42.0% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
67 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $4 · 66%
52-wk high $5
vs 200-day avg +2%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | -$0.3M | the first quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $0.7M | the fourth quarter of 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
APYX
this stock
Apyx Medical Corp
|
$162.89M | +11.1% | +9.9% | — | 0.6% |
|
ABT
Abbott Laboratories
|
$186.84B | -13.9% | +5.7% | 30.1 | 1.4% |
|
SYK
Stryker Corp
|
$129.09B | -1.1% | +11.2% | 39.0 | 1.8% |
|
MDT
Medtronic plc
|
$107.81B | -8.8% | +8.4% | 22.6 | 1.5% |
|
BSX
Boston Scientific Corp
|
$67.64B | -51.7% | +5.5% | 19.0 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| APYX | -9.1% | -6.7% | -3.2% | -13.4% | +11.1% |
| SPY | -0.4% | +1.4% | +6.3% | -1.0% | +8.4% |
| vs SPY | -8.7% | -8.1% | -9.5% | -12.3% | +2.8% |